Merger stub: the pociredir program shown below was discontinued on June 1, 2026. Fulcrum has agreed to a reverse merger with Slate Medicines; holders are to receive a pre-closing cash dividend of about $3.53 a share plus about 5% of the combined company. Stockholder vote December 3, 2026.
What they do
We are a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Our lead product candidate, pociredir, is an oral small molecule designed to induce fetal hemoglobin, or HbF, and is in clinical development for the treatment of sickle cell disease, or SCD.
Cash figures as of 2026-06-30. Database snapshot: 2026-11-11.
Share structure
Common
76.3M
Pre-funded warrants
0.0M
Options
11.6M
RSUs
0.0M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
2.4M
FDSO
90.4M
Cap table as of 2026-06-30.
Pociredir was discontinued on June 1, 2026 after the FDA concluded that PRC2-complex intervention carries malignancy risk in chronic indications (the Tazverik secondary-malignancy findings; Tazverik was withdrawn globally in March 2026), leaving no viable regulatory path for the program. Under the August 16, 2026 merger agreement with Slate Medicines, Fulcrum holders receive a pre-closing cash dividend of about $270M (about $3.53 a share on 76,381,948 shares at the October 28, 2026 record date) plus about 5% of the combined company, to trade as SLTE. Special meeting vote December 3, 2026, 9:00 a.m. ET; outside date February 28, 2027. The share counts, cash, and pipeline figures on this page are Fulcrum standalone, pre-merger, and the pociredir listing is historical, not an active program.
Price history
Loading FULC daily closes…
Loading price history…
Next catalyst
Pociredir · Mar 18 - Apr 29 in 41 mo · Phase 2 · Sickle Cell Disease
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 1 · TerminatedModality: small molecule (oral)
Target PRC2
Partnerships n/a (all rights retained)
Indications
Sickle cell disease (SCD)(Phase 1)
Status note Discontinued June 2026 following end-of-Phase-I meeting minutes (received late May 2026) reflecting heightened FDA concerns on benefit-risk in SCD, informed by preclinical hematologic malignancy observations with pociredir and malignancy signals reported with other PRC2 inhibitors. Company subsequently ceased R&D activities, initiated a restructuring (~85% workforce reduction) and is evaluating strategic alternatives.
losmapimod
Phase 3 · TerminatedModality: small molecule (oral)
Partnerships Genzyme/Sanofi (ex-U.S. commercialization license, May 2024; Sanofi terminated for convenience December 2024; agreement ended April 17, 2025)
Status note Development discontinued September 2024 following Phase 3 REACH topline results.
CAMP4-licensed DBA program
Preclinical · TerminatedModality: small molecule
Partnerships CAMP4 Therapeutics (worldwide exclusive license, July 2023; notice to terminate delivered April 23, 2026)
Indications
Bone marrow failure syndromes, including Diamond-Blackfan anemia (DBA)(Preclinical)
Status note Bone marrow failure syndromes program, including DBA, discontinued February 2026.
FTX-6274
Preclinical · ActiveModality: small molecule (oral)
Target EED
Indications
Prostate cancer(Preclinical)
Status note Oral EED inhibitor candidate; preclinical data presented at ESMO 2025. Company ceased R&D activities in June 2026 and is evaluating strategic alternatives; no product candidates in active clinical development.
Per-asset detail extracted from the 10-Q filed 2026-07-30. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.